Innovative Eyewear (NASDAQ:LUCY – Get Free Report) and Sanara MedTech (NASDAQ:SMTI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.
Insider & Institutional Ownership
1.0% of Innovative Eyewear shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 1.7% of Innovative Eyewear shares are held by company insiders. Comparatively, 42.0% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Innovative Eyewear and Sanara MedTech”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Innovative Eyewear | $2.66 million | 2.12 | -$7.59 million | ($1.69) | -0.52 |
| Sanara MedTech | $107.48 million | 1.96 | -$37.56 million | ($3.77) | -6.10 |
Innovative Eyewear has higher earnings, but lower revenue than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Innovative Eyewear, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Innovative Eyewear has a beta of 2.66, suggesting that its stock price is 166% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.
Profitability
This table compares Innovative Eyewear and Sanara MedTech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Innovative Eyewear | -272.42% | -83.37% | -76.02% |
| Sanara MedTech | -31.23% | -3.19% | -0.56% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Innovative Eyewear and Sanara MedTech, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Innovative Eyewear | 1 | 1 | 0 | 0 | 1.50 |
| Sanara MedTech | 2 | 0 | 2 | 0 | 2.00 |
Sanara MedTech has a consensus price target of $34.00, suggesting a potential upside of 47.89%. Given Sanara MedTech’s stronger consensus rating and higher possible upside, analysts plainly believe Sanara MedTech is more favorable than Innovative Eyewear.
Summary
Sanara MedTech beats Innovative Eyewear on 9 of the 14 factors compared between the two stocks.
About Innovative Eyewear
Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.
About Sanara MedTech
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Receive News & Ratings for Innovative Eyewear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovative Eyewear and related companies with MarketBeat.com's FREE daily email newsletter.
